Legend Biotech Corporation

LEGN

Equity

ISIN US52490G1022 / Valor 54834759

NASDAQ (2024-09-18)

USD 49.91-2.46%

Legend Biotech Corporation
UMushroom community rating:

4.00 4 votes No rating yet

NegativeNeutralPositive

About company

Legend Biotech Corporation is a biotechnology company focused on developing investigational agents and innovative technologies in personalized medicine, with a particular emphasis on cell therapies for treating hematological malignancies and solid tumors. The company is dedicated to exploring the potential of cell therapies to address diseases that are considered intractable and incurable. Through its pipeline of cutting-edge therapies, Legend Biotech aims to provide new treatment options for patients with challenging medical conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Legend Biotech Corporation reported collaboration revenue of $78.5 million for the first quarter of 2024, a significant increase from $36.3 million in the first quarter of 2023. This growth was primarily driven by increased sales of CARVYKTI® under the Janssen Agreement.

License Revenue

For the first quarter of 2024, Legend Biotech Corporation recognized $12.2 million in license revenue. This revenue was associated with the global license agreement with Novartis Pharma AG to develop, manufacture, and commercialize LB2102 and other potential CAR-T therapies targeting DLL3.

Net Loss Reduction

Legend Biotech Corporation reported a net loss of $59.8 million for the first quarter of 2024, a notable improvement compared to the net loss of $112.1 million in the first quarter of 2023. This reduction in net loss reflects the company's efforts to manage expenses and increase revenue.

Cash Position

As of March 31, 2024, Legend Biotech Corporation had cash and cash equivalents, time deposits, and short-term investments totaling $1.3 billion. The company believes this financial position will provide a runway into 2026, by which time it anticipates achieving operating profit.

Increased Expenses

Research and development expenses for Legend Biotech Corporation were $101.0 million in the first quarter of 2024, up from $84.9 million in the same period of 2023. The increase was primarily due to ongoing research and development activities for cilta-cel and investments in the company's solid tumor programs.

Summarized from source with an LLMView Source

Key figures

-25.2%1Y

13.9%3Y

%5Y

Performance

42.1%1Y

52.2%3Y

52.5%5Y

Volatility

9373 M

Market cap (USD)

167,231

Daily traded volume (Shares)

51.51 / 49.84

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.00

4 votes

Performance:

4.25

Innovation:

4.50

Society:

4.25

Nature:

4.00

Mike Panichella

Switzerland, 28 Aug 2024

Gemäss den Analystenschätzungen zum Umsatzwachstum des Standard & Poor's Konsensus gehört das Unternehmen mit zu den wachstumsstärksten. Die Rentabilität des Unternehmens vor Zinsen, Steuern und Abschreibungen zeichnet sich durch fragile Margen aus.